Abingdon Health Plc · LSE:ABDX
Abingdon Health — ShareSoc Manchester (May 2026)
18 slides from Abingdon Health's conference presentation, May 12, 2026
Slide 1: ShareSoc Manchester
ShareSoc Manchester 12 May 2026 Fast-tracking diagnostics and devices to improve lives OTCQB: ABDXF | LSE AIM: ABDX
Slide 2: Presenting Team
Presenting Team Chris Hand Tom Hayes Executive Chairman CFO Board Member Board Member ▪ Co-founder of Abingdon Health ▪ Joined Abingdon Health in January 2025 ▪ 30+ years’ experience in the medical diagnostics ▪ 10 years as Group Finance Director at Northern industry Bear plc, an AIM-listed Group of
Slide 3: LFT Journey | MedTech Is Changing Lives
LFT Journey | MedTech Is Changing Lives Pre-Pandemic Pregnancy tests the most widely known UpFront Diagnostics’ Stroke Detection Test lateral flow tests on the market LVOne: the world's first rapid test for identifying stroke at point of care. Results in <10 minutes. Challenge: Evolving project scop
Slide 4: Abingdon Health plc | Who We Are
Abingdon Health plc | Who We Are • Mission: Fast-tracking diagnostics and devices to improve lives • Founded in 2008, headquartered in York, UK; laboratory facilities in Doncaster UK, with US headquarters in Madison, Wisconsin • Specialist lateral flow CDMO in UK & USA • Full regulatory, quality and
Slide 5: Financial Summary
Financial Summary H1 FY26 | Six months ended 31 December 2025 TOTAL REVENUE INCL. GRANT FUNDED REPORTED REVENUE ADJ. EBITDA LOSS CASH AT 31 DEC 2025 £4.5m £4.2m £1.7m £3.7m ↑ 45% vs H1 FY25 ↑ 37% vs H1 FY25 Improved from £1.9m vs £1.9m at Jun 2025 REVENUE BY SEGMENT (£'000) REVENUE BY GEOGRAPHY — H1
Slide 6: Financial Summary
Financial Summary H1 FY26 | Six months ended 31 December 2025 REVENUE & GROWTH C AS H & C AP I T AL • Total H1 FY26 revenues up 45% to £4.5m (H1 • Placing and retail offer in October 2025 raising FY25: £3.1m), including grant-funded income £3.2m net of expenses to accelerate US expansion and support
Slide 7: Multi-year revenue summary
Multi-year revenue summary FY22–FY26E | £’000 | FY22 excludes COVID-19 revenues 14000 KEY METRICS £12.2m 12000 +40% +45% Revenue CAGR 10000 FY22–FY25 £8.4m 8000 +37% +45% £6.1m FY26E revenue growth vs FY25 6000 +52% £4.0m 4000 £12.2m +128% FY26E (broker estimate) £1.8m 2000 0 FY25 FY22 FY23 FY24 FY2
Slide 8: Lateral Flow Technology is Evolving
Lateral Flow Technology is Evolving Lateral flow is a powerful, rapid, flexible, on-site diagnostic technology: ▪ Single biomarker or multiplex capability ▪ Qualitative or quantitative ▪ Multiple sample matrices ▪ Competitive or sandwich assay format ▪ Gold, latex, carbon, polystyrene bead, fluoresc
Slide 9: Lateral Flow Immunoassay
Lateral Flow Immunoassay Control line Analyte 2 test line Absorbent pad Sample, containing analytes Nitrocellulose membrane Conjugated gold (immobilised) Analyte 1 test line Conjugate release pad Sample Pad In this format of test, line signal intensity increases with presence of antigen in sample. I
Slide 10: Advances: Reducing Plastic Waste
Advances: Reducing Plastic Waste 2024: $8.5 billion market 2035: $25.8 billion market* Clinical Testing Clinical Testing Veterinary Diagnostics Pregnancy Testing falls within clinical testing at $1.5bn in 2024 rising to $2.3bn by 2033** Approx 12g of single use plastic per test 2 billion+ lateral fl
Slide 11: Abingdon Health USA, Inc.
Abingdon Health USA, Inc. ▪ Abingdon Health USA, Inc entity was established with a commercial office and R&D laboratories fully operational at the Madison, WI, facility as of April 2025 and overseen by Abingdon co-founder, Chris Yates ▪ An increasing number of Abingdon clients are US-based with expl
Slide 12: Our First Year In Madison
Our First Year In Madison Apr26: ribbon cutting & US site launch at University Research Park, Madison, WI Q4-FY25: $2.5m contract win for US development of companion diagnostic test Sep25: Facility expansion following contract wins, incl Pharma CDx, veterinary, infectious diseases, food quality Nov2
Slide 13: USA | OTC Markets Launch
USA | OTC Markets Launch US Market Platform: Abingdon Health (OTCQB: ABDXF) will commence trading on the OTCQB Venture Market in the US on April 21st, making shares available to US investors in dollars during US trading hours ▪ US Expansion Context: The launch on OTCQB follows the Phase 2 expansion
Slide 14: LFT Use in Companion Diagnostics
LFT Use in Companion Diagnostics Role of Companion Diagnostics (CDx): ▪ CDx tools provide essential data to safely and effectively use specific therapeutic products at point of care. Regulatory and Validation Requirements: ▪ Lateral flow CDx devices require rigorous validation and must demonstrate c
Slide 15: Example CDx Development Timeline
Example CDx Development Timeline 2026 2027 2028 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 Drug Timeline Phase 1b/2a Phase 3 Operationally same clinical study, but separate regulatory submissions for CDx CDx Development PoC Op
Slide 16: Project Examples
Project Examples Delivering precision diagnostics across pharma, academia & global health 4TEEN4 Pharmaceuticals Companion Diagnostic for Invobenitug First-in-class lateral flow CDx for cDPP3-targeted cardiogenic shock therapy. Developed to identify patients likely to benefit from Invobenitug; no ap
Slide 17: Summary Highlights
Summary Highlights 1 Lateral flow power and flexibility resonating together with full-service offering 2 Illustrated via recent contract wins: £4.8m and $2.5m in March 2026 3 US manufacturing expansion underway in Madison, Wisconsin 4 Complemented by complete IVD and Medtech regulatory capability 5
Slide 18: Any Questions?
Any Questions? Nina Garrett: nina.garrett@abingdonhealth.com Abingdon Health: Fast-tracking Design | Development diagnostics | Manufacturing and devices to improve lives | Packaging | Performance Evaluation| OTCQB: Regulatory ABDXF | LSE Support AIM: ABDX 18